MedPath

Neurocognitive Follow-Up (FU) Study

Completed
Conditions
Cognitive Developmental Delay
Interventions
Other: Neurocognitive Follow-up
Registration Number
NCT04962035
Lead Sponsor
Société des Produits Nestlé (SPN)
Brief Summary

This is a follow-up study of a recently completed trial (17.14.INF) evaluating the growth of pre-term infants. Enrolled children will undergo neurocognitive assessments at 18- and 24-months of corrected age (CA).

Detailed Description

This is a follow-up study of a recently completed multi-center, prospective, single-arm, open-label interventional trial (17.14.INF - Alprem RTF: NCT03728764) evaluating the growth of pre-term infants receiving a two-stage PTF feeding system while in the neonatal care unit and continuing until 30 days post-discharge.

Enrolled children will undergo neurocognitive assessments at 18- and 24-months of corrected age (CA). The timing of the cognitive assessments aligns with routine check-up visits and reflect the period at which developmental delays may first become evident.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
21
Inclusion Criteria
  1. Infants / children born prematurely who were enrolled into the original clinical trial and who are less than 24 m of CA.
  2. Having obtained his / her parents' (or his or her legally accepted guardian written informed consent and having evidence of personally signed and dated informed consent document indicating that the child's parent(s) / legal guardian has been informed of all pertinent aspects of the study.
Exclusion Criteria
  1. Infants identified retrospectively as not meeting the inclusion or exclusion criteria for the original study.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Alprem RTF Brain Follow-upNeurocognitive Follow-upNeurocognitive Follow-up of children previously having participated in the Alprem RTF study
Primary Outcome Measures
NameTimeMethod
Bayley-III scores at 24 months24 months of CA

Bayley Scales of Infant and Toddler Development, third edition (Bayley-III) cognitive score at 24 months of corrected age (CA). Composite scores range 40-160, with a mean of 100 and SD of 10 points. A composite score of 70 or less is an indication of a delay in child neurocognitive development.

Secondary Outcome Measures
NameTimeMethod
Bayley-III scores at 18 months18 months of CA

Bayley Scales of Infant and Toddler Development, third edition (Bayley-III) cognitive score at 18 months of corrected age (CA). Composite scores range 40-160, with a mean of 100 and SD of 10 points. A composite score of 70 or less is an indication of a delay in child neurocognitive development.

Child temperament scoresAt 18 and 24 months of CA

Parent-reported child temperament questionnaire validated specifically for children between the ages of 18 and 36 months

Number of healthcare usageAt 18 and 24 months of CA

Retrospective parent-reported recall of the number of healthcare usage and hospitalizations

Feeding patternsAt 18 and 24 months of CA

Feeding practice outcomes collected retrospectively at each visit via a parent-reported questionnaire related to breastfeeding duration, prevalence of formula feeding, and age at initiation of complementary feeding

Head circumferenceAt enrollment, 18 and 24 months of CA

Child head circumference (cm)

Developmental Milestone scoresAt 18 and 24 months of CA

Parent-reported achievements of specific age-appropriate milestones (yes/no responses to child performing specific milestones or not)

WeightAt enrollment, 18 and 24 months of CA

Child weight (g)

Length/heightAt enrollment, 18 and 24 months of CA

Child length/height (cm)

Trial Locations

Locations (3)

Klinika Chorob Dzieci, Uniwersytecki Szpital Dzieciecy

🇵🇱

Krakow, Poland

Univerzitna nemocnica Martin

🇸🇰

Martin, Slovakia

Fakultna nemocnica s poliklinikou Nove Zamky

🇸🇰

Nove Zamky, Slovakia

© Copyright 2025. All Rights Reserved by MedPath